As of January 13, 2020, each new patient registering for the first time at the Radboudumc is actively asked for consent to use his/her residual biomaterial, clinical imaging and medical data for scientific research. To date, there has been no major organizational obstacles in the implementation of this new consent procedure. However, its impact on available material and data is still under evaluation. In addition to quantitative analyses, qualitative research exploring underlying motivations of patients who consent or do not consent to the use of their material and data will also be performed. This feasibility study will be further expanded to assess the impact of the new consent procedure on vulnerable patient groups, i.e. children (<16 years old), acute care patients, and incapacitated patients.
For further information, please visit our website, “Use of medical data and leftover biomaterial” (available in Dutch only), or contact Dr. Jennifer Lutomski, project leader, at Jennifer.Lutomski@radboudumc.nl.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New Automated PBMC isolation method introduced in LMI.21 September 2021
The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.read more
Lysine Metabolism sub-biobank21 September 2021
Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.read more